Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, 8-k
Related Tickers: APVO
TL;DR
APVO filed an 8-K updating corporate info, no major news yet.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on September 16, 2025, reporting on other events and financial statements. The filing provides updated company information, including its principal executive offices located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121, and its telephone number as (206) 838-0500.
Why It Matters
This 8-K filing serves as an official update for investors and the public regarding Aptevo Therapeutics Inc.'s corporate information and any significant events or financial disclosures.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information that inherently increases risk for investors.
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- 2401 4th Avenue Suite 1050 (address) — Principal Executive Offices
- Seattle, Washington (location) — Principal Executive Offices City and State
- 98121 (zip_code) — Principal Executive Offices Zip Code
- (206) 838-0500 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Aptevo Therapeutics Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 16, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 16, 2025.
What is the exact address of Aptevo Therapeutics Inc.'s principal executive offices?
The address of Aptevo Therapeutics Inc.'s principal executive offices is 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
What is the telephone number for Aptevo Therapeutics Inc.?
The telephone number for Aptevo Therapeutics Inc., including area code, is (206) 838-0500.
What is the Commission File Number for Aptevo Therapeutics Inc.?
The Commission File Number for Aptevo Therapeutics Inc. is 001-37746.
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-16 17:07:43
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20250916.htm (8-K) — 44KB
- apvo-ex99_1.htm (EX-99.1) — 30KB
- img237228349_0.jpg (GRAPHIC) — 14KB
- 0001193125-25-205107.txt ( ) — 205KB
- apvo-20250916.xsd (EX-101.SCH) — 24KB
- apvo-20250916_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On September 16, 2025, Aptevo Therapeutics Inc. (the "Company") issued a press release announcing a 100% remission rate in Cohort 3 of its Phase 1b/2 RAINIER trial evaluating mipletamig, the Company's first-in-class CD123 x CD3 bispecific antibody, in combination with venetoclax + azacitidine for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press release of Aptevo Therapeutics Inc. dated September 16, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: September 16, 2025 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer